The efficacy of a serum carboxyterminal pyridinoline cross-linked telopeptide of type I collagen as a quantitative screening marker for bone metastases in patients with urological malignancies

Stepan, 1989, Bone alkaline phosphatase isoenzyme and urinary hydroxyproline in healthy subjects, patients with osteolytic metastasis, and patients with primary hyperparathyroidism, Neoplasia, 36, 495 Coleman, 1988, Biochemical prediction of response of bone metastases to treatment, Br. J. Cancer, 58, 205, 10.1038/bjc.1988.194 Takeuchi, 1994, Assay of urinary pyridinoline and deoxypyridinoline as potential markers of the rate bone resorption: usefulness of urinary pyridinoline and deoxypyridinoline in patients with prostate cancer with bone metastasis, Jpn. J. Urol., 85, 1521, 10.5980/jpnjurol1989.85.1521 Yoneda, 1998, Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone, Eur. J. Cancer, 34, 240, 10.1016/S0959-8049(97)10132-0 Tähtelä, 1996, Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy- and aminoterminal propeptides (PIPC, PINP) as markers of metastatic bone disease in breast cancer, Anticancer Res., 16, 2289 Koizumi, 1999, Bone metabolic markers in bone metastasis of breast cancer, Int. J. Clin. Oncol., 4, 331, 10.1007/s101470050080 Horiguchi, 2000, Usefulness of serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of bone metastasis from lung cancer, Jpn. J. Clin. Oncol., 30, 174, 10.1093/jjco/hyd043 Kylmälä, 1993, Evaluation of the effect of oral clodronate on skeletal metastases with type I collagen metabolites: a controlled trial of the Finnish prostate cancer group, Eur. J. Cancer, 29, 821, 10.1016/S0959-8049(05)80417-4 Yoshida, 1997, Serum concentration of type I collagen metabolites as a quantitative marker of bone metastases in patients with prostate carcinoma, Cancer, 80, 1760, 10.1002/(SICI)1097-0142(19971101)80:9<1760::AID-CNCR10>3.0.CO;2-3 Maeda, 1997, Correlation between bone metabolic markers and bone scan in prostatic cancer, J. Urol., 157, 539, 10.1016/S0022-5347(01)65196-6 Eriksen, 1993, Serum markers of type I collagen formation and degradation in metabolic bone disease: collelation with bone histomorphometry, J. Bone Miner. Res., 8, 127, 10.1002/jbmr.5650080202 Risteli, 1993, Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal teropeptide of I collagen: a new serum marker of bone collagen degradation, Clin. Chem., 39, 635, 10.1093/clinchem/39.4.635 Risteli, 1993, Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation, Clin. Chem., 39, 635, 10.1093/clinchem/39.4.635 Zweig, 1993, Receiver operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine, Clin. Chem., 39, 561, 10.1093/clinchem/39.4.561 Kairisto, 1995, Software for illustrative presentation of basic clinical characteristics of laboratory tests—GraphROC for Windows, Scand. J. Clin. Lab. Invest., 55, 37, 10.3109/00365519509088449 Elomaa, 1992, Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma, Br. J. Cancer, 66, 337, 10.1038/bjc.1992.266 Akimoto, 1998, Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis, Endocline J., 45, 97, 10.1507/endocrj.45.97 Koizumi, 1998, Bone metabolic markers in metastatic bone tumors, Cancer J., 3, 137